Ignite Creation Date:
2025-12-26 @ 11:14 AM
Ignite Modification Date:
2026-01-01 @ 12:36 AM
Study NCT ID:
NCT06487728
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2024-07-05
First Post:
2024-06-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Validity of Urinary Titin and Skeletal Muscle Index as Predictor of Muscle Weakness in Critically Ill Patients. A Prospective Cohort Study
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 161}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'ENROLLING_BY_INVITATION', 'startDateStruct': {'date': '2024-07-01', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-06', 'completionDateStruct': {'date': '2025-02-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2024-06-27', 'studyFirstSubmitDate': '2024-06-27', 'studyFirstSubmitQcDate': '2024-06-27', 'lastUpdatePostDateStruct': {'date': '2024-07-05', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2024-07-05', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-01-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The relationship between cumulative urinary titin level and rate of rectus femoris muscle atrophy on days 1 and 7 of ICU admission', 'timeFrame': 'At day 1 and 7 day of icu admission', 'description': 'Measurement of urinary titin level and its correlation to muscle index'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Urinary Titin']}, 'descriptionModule': {'briefSummary': "Although skeletal muscle atrophy is common in critically ill patients, biomarkers associated with muscle atrophy have not been identified reliably. Titin is a spring-like protein found in muscles and has become a measurable biomarker for muscle breakdown and intensive care unit-acquired weakness in critically ill patients, in whom titin loss is a possible pathophysiology. The skeletal muscle index (SMI) is an alternative biomarker for muscle weakness, which is calculated by dividing the cross-sectional area (cm2) of the skeletal muscle at the level of the third lumbar vertebra by the square of the patient's height (m2) on CT The possibility of using urinary titin and skeletal muscle index for early prediction of muscle weakness in critically ill patients.", 'detailedDescription': "All patients will be subjected to the following:\n\nInformed consent will be obtained from patients. History taking including age, sex, comorbidities, current medications, ethnicity, reason for admission, and body mass index (BMI). General clinical examination. General laboratory investigations: (CBC, Random blood sugar, CRP, ESR).\n\nUrinary Titin Measurement:\n\nThe first urine sample will be collected using a urethral catheter within 12 h of ICU admission and 24-hour urine samples d 24-hour urine samples on days 2, 3, 5, and 7.\n\nUrinary titin will be measured using an ELISA kit (Maruyama et al., 2016).\n\nSkeletal Muscle Index calculation:\n\nThis assessment calculates the skeletal muscle index (SMI) (cm2/m2) by dividing the cross-sectional area (cm2) of the skeletal muscle at the level of the third lumbar vertebra (L3) by the square of the patient's height (m2) on CT. SMI measured using CT. ( Mitobe et al. 2019).\n\nUltrasonographic Measurement:\n\nRectus femoris muscle area and diaphragm thickness will be evaluated with serial ultrasound measurements on days 1, 3, 5, and 7 of ICU admission. Recordings will be discontinued at death or ICU discharge. Cross-sectional area of the rectus femoris muscle will be evaluated at the midway between the anterior superior iliac spine and the proximal 9 end of the patella. A transducer will be placed perpendicularly to the long axis of the rectus femoris muscle with patients in the supine position under passive knee extension.\n\nThe diaphragm will be evaluated at the zone of apposition on the right chest wall. Its thickness will be measured during the end-expiration phase. Beds will be adjusted at a 30° angle. We will exclude patients whose diaphragm is unclear or difficult to measure.\n\nPatients will be divided into three groups according to the changes in diaphragm thickness: atrophy, unchanged, and increased. A 10% change in diaphragm thickness will be regarded as the cutoff value in the three groups. Atrophy will be first classified with \\>10% decrease in diaphragm thickness from day 1 to the lowest value over the measurement period. Thereafter, increased thickness group will be classified when \\>10% increase is observed. The rest of the patients were classified into the unchanged group, as previously reported (Nakanishi et al., 2019). In the analysis, the unchanged group will be compared with atrophy and increased groups and their combination because both increased and decreased diaphragm thickness significantly influence clinical outcomes (Goligher et al., 2018). Rectus femoris cross-sectional area and diaphragm thickness will be measured thrice, and the median value was used for evaluation. All measurements will be conducted by two examiners. Intraclass and interclass correlation coefficients will be 0.99 and 0.99 for rectus femoris cross-sectional area and 0.95 and 0.95 for diaphragm thickness, respectively.\n\nPhysical Assessment and Mobilization:\n\nWhen patients are awake and attentive, physical therapists will be evaluated the Medical Research Council (MRC) score and incidence of ICU-AW on days 1 and 7 of ICU admission. Intact level of consciousness and awareness will be defined by patient's response to at least three of five orders (De Jonghe et al., 2007).\n\nICU-AW will be defined as an MRC score of \\<48 on two separate occasions (Stevens et al., 2009). We will use the incidence of ICU-AW following the last measurement for comparison. 10 IMS is a measure of mobilization capabilities from 0 (lying in bed) to 10 (walking independently) (Hodgson et al., 2014). We will evaluate maximum IMS score during the study period because the maximum level of mobility is an important prognostic factor (Kim et al., 2019)."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'genderBased': True, 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Critically ill patients', 'genderDescription': 'Both sex', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\nConsent from relatives of first degree. Consecutive adult patients who will be expected to remain in ICU for \\>5 days will be enrolled. Nonsurgical critically ill patients will be included because surgical insult reportedly increased urinary titin level (Tanihata et al., 2019). Age more than 18 years. Both male and female.\n\nExclusion Criteria:\n\nSurgery not including percutaneous abscess drainage. Patients with expected prehospital functional status of \\<48 hours. Chest tube insertion, and tracheostomy in ICU. 8 Current pregnancy. Diagnosis of primary neuromuscular disease. Trauma at the measurement point.'}, 'identificationModule': {'nctId': 'NCT06487728', 'briefTitle': 'The Validity of Urinary Titin and Skeletal Muscle Index as Predictor of Muscle Weakness in Critically Ill Patients. A Prospective Cohort Study', 'organization': {'class': 'OTHER_GOV', 'fullName': 'Zagazig University'}, 'officialTitle': 'The Validity of Urinary Titin and Skeletal Muscle Index as Predictor of Muscle Weakness in Critically Ill Patients. A Prospective Cohort Study', 'orgStudyIdInfo': {'id': '386/10-June 2024'}}, 'armsInterventionsModule': {'interventions': [{'name': 'Urinary titin', 'type': 'DIAGNOSTIC_TEST', 'description': 'Urinary titin and skeletal muscle index as predictor of muscle wasting in critically ill patient'}]}, 'contactsLocationsModule': {'locations': [{'city': 'Zagazig', 'state': 'Sharqia Province', 'country': 'Egypt', 'facility': 'Faculty of medicine, Zagazig university', 'geoPoint': {'lat': 30.58768, 'lon': 31.502}}]}, 'ipdSharingStatementModule': {'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF'], 'ipdSharing': 'YES'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Zagazig University', 'class': 'OTHER_GOV'}, 'responsibleParty': {'type': 'SPONSOR'}}}}